DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Anturane (Sulfinpyrazone) - Summary

 
 



ANTURANE SUMMARY

Anturane®

Anturane, sulfinpyrazone USP, is a uricosuric agent available as 100-mg tablets and 200-mg capsules for oral administration.

Anturane is indicated for the treatment of:

  1. Chronic gouty arthritis
  2. Intermittent gouty arthritis

See all Anturane indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Anturane (Sulfinpyrazone)

Common Gout Drug Tied to Lower Risk of Early Death in Study
Source: MedicineNet allopurinol Specialty [2014.03.31]
Title: Common Gout Drug Tied to Lower Risk of Early Death in Study
Category: Health News
Created: 3/28/2014 2:36:00 PM
Last Editorial Review: 3/31/2014 12:00:00 AM

Gout isn't always easy to prove: Study finds CT scans help catch cases traditional test misses
Source: Arthritis / Rheumatology News From Medical News Today [2014.03.28]
Gout is on the rise among U.S. men and women, and this piercingly painful and most common form of inflammatory arthritis is turning out to be more complicated than had been thought.

CT Can Help Spot Gout
Source: MedPage Today Radiology [2014.03.27]
(MedPage Today) -- Dual-energy CT may help in the definitive diagnosis of gout, which can sometimes be missed with microscopic crystal analysis alone, a prospective study suggested.

Gout drug may reduce risk of death
Source: Gout News From Medical News Today [2014.03.26]
In a recently to be published study in Annals of the Rheumatic Diseases, researchers have found the use of the drug allopurinol was associated with a reduced risk of death in hyperuricemic (gout)...

UK rates of gout soaring, but treatment remains poor
Source: Gout News From Medical News Today [2014.01.16]
UK rates of gout have soared since the late1990s, with one in every 40 people now affected by the condition - the highest in Europe - but treatment remains as poor now as it was then, reveals...

more news >>

Published Studies Related to Anturane (Sulfinpyrazone)

The effect of sulfinpyrazone on treadmill exercise-induced angina pectoris. [1993]
Suspecting that platelet thromboemboli could play a role in the pathogenesis of myocardial ischemia, we have done a random-order, double-blind, crossover study of the effect of the platelet-active drug sulfinpyrazone on treadmill exercise-induced angina pectoris in 30 men with coronary artery disease.

Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. [2000.12]
BACKGROUND: Management of cyclosporine (CsA)-associated hyperuricemia in heart transplantation (HT) is difficult. Because of the myelotoxicity of combined allopurinol and azathioprine, we tested sulfinpyrazone... However, this drug reduced CsA levels, thus the risk of rejection is present.

Effects of sulfinpyrazone on retinal damage induced by experimental diabetes mellitus in rabbits. [1998.08]
The protective activity of the phenylbutazone derivative, sulfinpyrazone on retinal lesions has been assessed in rabbits with severe streptozotocin-induced diabetes. Sulfinpyrazone (8 mg kg-1 per day per os) was administered in diabetic animals in two different experimental procedures: for 135 days in a preventive approach (beginning on the day of initial hyperglicaemia); and for 30 days in a therapeutic approach (beginning on the day of appearance of severe retinal damage)...

Acute renal failure due to sulfinpyrazone. [1998.05]
A case of sulfinpyrazone-associated acute renal failure is reported. Sulfinpyrazone can cause reversible acute renal failure from acute tubular necrosis in patients with volume depletion.The patients at risk for acute renal failure due to sulfinpyrazone are those who have intravascular volume depletion as sensed by the kidneys.

Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. [1991.06.15]
We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis... A relatively high rate of complications, particularly mild gastrointestinal bleeding, was noted in patients on aspirin/sulfinpyrazone that could not be predicted on the basis of pre-treatment hemostatic test results.

more studies >>


Page last updated: 2014-03-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012